Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 18;130(21):2243–2250. doi: 10.1182/blood-2017-07-793786

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 by The American Society of Hematology

PMC Copyright notice

Figure 5. — Heat map of change in biomarker levels from baseline by time after ibrutinib dose. Heat map of chemokines, cytokines, or factors associated with fibrosis that showed a significant change in levels for at least 1 time point posttreatment. The values at each time point are expressed as a proportion of the baseline value and depicted as a heat map. *P < .05; **P < .01; ***P < .001; ****P < .0001. CXCL9, C-X-C motif chemokine ligand 9; CXCL10, C-X-C motif chemokine ligand 10; EGF, epidermal growth factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-g, interferon-γ; IL-1a, interleukin-1α; IL-8, interleukin-8; MCP-1, monocyte chemotactic proteins 1; MCP-3, macrophage-derived chemokine, monocyte chemotactic proteins 3; MDC, macrophage-derived chemokine; MIP-1a, macrophage-inflammatory proteins 1α; MIP-1b, macrophage-inflammatory proteins 1β; sCD25, soluble CD25; TNFa, tumor necrosis factor-α.